Physician profile
Kofi Appiah
NPI 1346200961
$7,130.53
in general payments reported to CMS, 2019-2025
30 companies · $1,223 in 2025
The $1,223 reported for 2025 was more than what 82% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $537 · 2020: $913 · 2021: $1,081 · 2022: $1,295 · 2023: $938 · 2024: $1,143 · 2025: $1,223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,167 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,166.80 |
| Education | $136.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $643.20 | 2019-2025 | Tavneos, Krystexxa |
| Otsuka America Pharmaceutical, INC. | $610.91 | 2019-2025 | Jynarque, Voyxact |
| Horizon Therapeutics Plc | $569.57 | 2019-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $545.41 | 2020-2025 | Acthar, Terlivaz |
| Vifor Pharma, INC. | $450.08 | 2020-2025 | Veltassa |
| Novartis Pharmaceuticals Corporation | $425.31 | 2020-2025 | |
| Akebia Therapeutics INC | $411.64 | 2019-2025 | Vafseo, Auryxia |
| Bayer Healthcare Pharmaceuticals INC. | $365.72 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $344.14 | 2019-2025 | Lokelma, Farxiga |
| Calliditas Therapeutics US INC. | $331.17 | 2023-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $327.60 | 2023-2025 | Filspari |
| Aurinia Pharma U.S., INC. | $317.08 | 2021-2025 | Lupkynis |
| Opko Pharmaceuticals, LLC | $309.78 | 2019-2024 | Rayaldee |
| Glaxosmithkline, LLC. | $302.08 | 2019-2023 | Benlysta, Jesduvroq |
| Mallinckrodt Enterprises LLC | $205.81 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $168.99 | 2022-2024 | Purified Cortrophin Gel |
| Novo Nordisk INC | $162.98 | 2024-2025 | Rivfloza, Ozempic, Wegovy |
| Daiichi Sankyo INC. | $101.92 | 2019-2023 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.36 | 2024 | Jardiance |
| Nuwellis, INC. | $81.30 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $66.75 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $62.75 | 2022-2024 | Ultomiris |
| Recor Medical INC | $50.78 | 2025 | Paradise Ultrasound Renal Denervation System |
| Renalytix Ai, INC. | $41.05 | 2022 | |
| Ardelyx, INC. | $38.05 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $29.62 | 2024-2025 | Jardiance |
| Scpharmaceuticals INC. | $26.64 | 2025 | |
| Rockwell Medical, INC. | $23.00 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $16.47 | 2019 | |
| Fresenius USA Marketing, INC. | $15.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kofi Appiah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.